Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human erythropoietin Fc fusion protein
- Development stage
- Phase 2
- Lead developer
- Dongguan Taili Bioengineering
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Recombinant human erythropoietin Fc fusion protein is a long-acting erythropoiesis-stimulating agent (ESA) being developed by Dongguan Taili Bioengineering for the treatment of renal anemia in patients with chronic kidney disease (CKD). The drug is a biologic fusion protein consisting of human erythropoietin (EPO) linked to an immunoglobulin Fc fragment (IgG1). This fusion is designed to extend the in vivo half-life of EPO by utilizing the neonatal Fc receptor (FcRn) recycling pathway, thereby reducing the frequency of administration compared to first-generation recombinant human EPO. It acts as an agonist of the erythropoietin receptor (EPOR), stimulating the JAK2/STAT5 signaling pathway to promote the proliferation and differentiation of erythroid progenitor cells into mature red blood cells. It is currently in Phase II clinical trials in China for patients undergoing hemodialysis or peritoneal dialysis.
- Other names
- 重组人红细胞生成素（Fc）融合蛋白注射液recombinant human erythropoietin (Fc) fusion protein
02
Targets
C1Q (Complement C1q)Erythropoietin ReceptorFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on recombinant human erythropoietin Fc fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human erythropoietin Fc fusion protein.